and sensitivity. [4] Since the attenuation coefficient of X-ray is highly correlated with tissue density, [5] the current positive CT contrast agents (PCTCAs) exhibit high CT density value (CT-DV) and provide contrast enhancement in CT imaging. [6] However, CT with PCTCAs fails to accurately detect diseases that have similar X-ray attenuations to surrounding tissues, such as osteosarcoma, the most common primary bone malignancy in skeletal system disease. [7] For example, enhanced CT scanning can barely distinguish osteosarcoma from surrounding bones in high energy level images. This is because bones and PCTCAs of high-Z elements such as iodide, the lutecium-based upconversion nanoparticles, [8] can generate similar X-ray attenuations and then result in analogous high CT density between them. Consequently, PCTCAs suffer from insufficient ability to distinguish osteosarcoma from bones. Rationally reducing the density of osteosarcoma can enhance the contrast between osteosarcoma and bone, which is propitious to detect osteosarcoma sensitively.How can we reduce the density of osteosarcoma? A phenomenon in clinical CT lung inspection demonstrates the lung has lower CT density than the surrounding tissues. Briefly, in CT The current positive computed tomography (CT) contrast agents (PCTCAs) including clinical iodides, present high CT density value (CT-DV). However, they are incapable for the accurate diagnosis of some diseases with high CT-DV, such as osteosarcoma. Because bones and PCTCAs around osteosarcoma generate similar X-ray attenuations. Here, an innovative strategy of negative CT contrast agents (NCTCAs) to reduce the CT-DV of osteosarcoma is proposed, contributing to accurate detection of osteosarcoma. Hollow mesoporous silica nanoparticles, loading ammonia borane molecules and further modified by polyethylene glycol, are synthesized as NCTCAs for the diagnosis of osteosarcoma. The nanocomposites can produce H 2 in situ at osteosarcoma areas by responding to the acidic microenvironment of osteosarcoma, resulting in nearly 20 times reduction of CT density in osteosarcoma. This helps form large CT density contrast between bones and osteosarcoma, and successfully achieves accurate diagnosis of osteosarcoma. Meanwhile, The NCTCAs strategy greatly expands the scope of CT application, and provides profound implications for the precise clinical diagnosis, treatment, and prognosis of diseases.